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List of Abbreviations 
 
ABCG5/8 ATP-binding cassette G5/8, ACC1 Acetyl-CoA carboxylase, ACS1 Acetyl-CoA synthase 1, 
AP Advanced pregnancy, ARL7 ADP-ribosylation factor like 7, ATGL Adipose triglyceride 
lipase,CD36 Cluster of differentiation, CYP51 Lanosterol 14α-demethylase, DGAT1/2 Diglyceride 
acyltransferase 1 and 2, DKO double knockout, EP Early pregnancy, FATP4 fatty acid transport protein, 
FABP-pm plasma membrane fatty acid binding protein, GDM Gestational diabetes mellitus, HMGCR 3-
hydroxy-3methylglutaryl coenzyme A reductase, HSL Hormone-sensitive lipase, LDLR LDL receptor, 
LXR Liver X receptor, MGL Monoglycerol lipase, NPC1L1 Niemann-Pick C1 like 1,  SCD1 Stearoyl-
CoA desaturase 1, SRB1 Scavenger receptor B1, SREBP1c Sterol-regulatory element-binding protein 1c, 
SREBP2  Sterol-regulatory element-binding protein 2. 
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Abstract 
Human pregnancy is associated with enhanced de novo lipogenesis in the early stages followed by 
hyperlipidemia during advanced gestation. Liver X receptors (LXRs) are oxysterol-activated nuclear 
receptors which stimulate de novo lipogenesis and also promote the efflux of cholesterol from 
extrahepatic tissues followed by its transport back to the liver for biliary excretion. Although LXR is 
recognized as a master regulator of triglyceride and cholesterol homeostasis it is unknown whether it 
facilitates the gestational adaptations in lipid metabolism. To address this question, biochemical profiling, 
protein quantification and gene expression studies were used, and gestational metabolic changes in 
T0901317-treated wild-type mice and LXRα, β-/- mutants were investigated.  Here, we show that altered 
LXR signaling contributes to the enhanced lipogenesis in early pregnancy by increasing the expression of 
hepatic Fas and stearoyl-CoA desaturase 1 (Scd1). Both the pharmacological activation of LXR with 
T0901317 and the genetic ablation of its two isoforms disrupted the increase in hepatic fatty acid 
biosynthesis and the development of hypertriglyceridemia during early gestation. We also demonstrate 
that absence of LXR enhances maternal white adipose tissue lipolysis, causing abnormal accumulation of 
triglycerides, cholesterol and free fatty acids in the fetal liver. Together, these data identify LXR as an 
important factor in early-pregnancy lipogenesis which is also necessary to protect against abnormalities in 
fetoplacental lipid homeostasis. 
 
Keywords: nuclear receptors/ LXR, pregnancy, liver, lipid and lipoprotein metabolism, triglycerides 
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Introduction 
Pregnancy is a dynamic state involving profound changes in the hormonal milieu of the mother which 
then signal adaptations in maternal nutrient metabolism. These adaptations are necessary in order to 
ensure a continuous supply of essential metabolites to support the growth and the development of the 
fetus as well as to provide the mother with sufficient energy stores to meet the demands of pregnancy and 
prepare for lactation (15, 26). Pregnancy-induced changes in energy and nutrient metabolism follow a 
biphasic pattern. Early pregnancy is mainly anabolic since it is associated with augmented lipid 
deposition in maternal tissues as a consequence of maternal hyperphagia, increased de novo lipogenesis 
and enhanced insulin sensitivity (15). In contrast, advanced pregnancy is an overall catabolic state 
involving augmented hydrolysis of stored lipids, hyperlipidemia and insulin resistance (15). 
 
Liver X receptors LXRα (NR1H3) and LXRβ (NR1H2) are oxysterol-activated nuclear receptors with key 
roles in the regulation of lipid metabolism. The two LXR isoforms share considerable sequence 
homology, but their tissue distribution differs: LXRα is highly expressed in liver, intestine, adipose tissue 
and macrophages whereas LXRβ is ubiquitously expressed (31). LXR stimulates de novo lipogenesis by 
increasing the expression of sterol-regulatory element-binding protein-1c (SREBP1c), a master 
transcriptional regulator of fatty acid and triglyceride synthesis (32, 34). LXR also binds directly to the 
promoters of the lipogenic enzymes fatty acid synthase (FAS), stearoyl-CoA desaturase 1 (SCD1) and 
acetyl-CoA carboxylase 1 (ACC1) (9, 18, 38). Moreover, LXR plays a pivotal role in the regulation of 
cholesterol homeostasis: upon activation, it drives the efflux of cholesterol from non-hepatic tissues (e.g. 
macrophages and enterocytes), stimulates biliary excretion of the sterol in the liver and reduces the 
intestinal absorption of luminal sterols (27, 30, 32, 40). However, there is limited understanding of how 
this nuclear receptor controls lipid metabolism in the physiological settings of pregnancy. Detailed 
knowledge of the molecular mechanisms responsible for lipid homeostasis during pregnancy is important 
as evidenced by the numerous reports demonstrating that failure to maintain the levels of circulating 
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lipids and lipoproteins within physiological ranges throughout gestation results in maternal dyslipidemia 
and fetal metabolic complications such as macrosomia and increased risk of type 2 diabetes mellitus in 
adulthood (19, 23, 39). 
 
We hypothesized that alterations in LXR activity could contribute to the gestational adaptations in lipid 
metabolism during pregnancy. Wild-type mice challenged with T0901317 (a potent and highly specific 
synthetic LXR agonist) throughout gestation and LXRα, β-/- mutants were used to examine the role of 
LXR in pregnancy metabolic adaptations. In the present study, we identify changes in LXR signaling as 
an important factor that influences early-pregnancy lipogenesis in mice. Our data also suggest that LXR 
protects against abnormalities in fetoplacental lipid homeostasis during murine pregnancy. 
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Materials and Methods 
Animal experiments. C57BL/6 mice were purchased from Harlan Laboratories (UK). LXR wild-type 
(WT) and LXRα, β-/- (LXR DKO; model previously described (27) were maintained on a mixed strain 
background (C57BL/6: Sv129). All the mice were housed in a temperature and light-controlled 
environment with 12-hour light/ 12-hour dark cycles. Age-matched mice had free access to water and 
were fed a standard chow diet or chow supplemented with 0.012% T0901317 (Cayman Chemicals, UK) 
(34) (T0901317 diet). Pregnant females were sacrificed on days 7, 10, 14 and 18 of gestation. Tissues and 
sera were collected from chow-fed virgin controls and non-pregnant mice fed with a T0901317 diet for a 
period of 7, 10, 14 or 18 days. Mice, fasted for 4 hours with free access to water, were sacrificed by CO2 
asphyxiation. All studies were conducted in conformity with the Public Health Service (PHS) Policy on 
Humane Care and Use of Laboratory Animals and were approved by local animal ethics committees in 
King’s College London and were authorised by the Home Office. 
 
Lipid analysis. Lipid extraction was performed as previously described (25). Briefly, frozen tissue 
fragments were homogenized in Hank’s Balanced Salt Solution using TissueLyser II system (Qiagen, 
UK) for 2 minutes at 30Hz and then centrifuged the samples at 12000 rpm for 15minutes at 4o C. The 
supernatant was discarded and the pellet was then re-suspended in 500μL of potassium phosphate lysis 
buffer with Triton-X100. The samples were then sonicated for 8 minutes at 4o C (a 30 seconds sonication 
phase followed by a 30 seconds resting phase) using a Bioruptor Plus system (Diagenode, Belgium). 
Following a centrifugation at 10000rpm for 20 minutes at 4oC, the supernatants were transferred to clean 
glass containers and were stored at -80o C. Serum and tissue extracts were processed and tested in the lab 
of Dr Eugene Jansen (Laboratory for Health Protection Research, National Institute of Public Health and 
the Environment, Netherlands). Beckman Synchron LX20 chemistry analyser (Beckman Coulter, UK) 
and commercially available kits were used for the measurement of  total cholesterol (467825, Beckman 
Coulter, UK), HDL-cholesterol (467820, Beckman Coulter, UK), triglycerides (445850, Beckman 
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Coulter, UK) and free fatty acids (NEFA-HR(2) assay kit, Wako-Diagnostics, USA) ; measurements were  
normalized to tissue protein content as previously described (25). 
 
RNA isolation, cDNA synthesis and quantitative real-time PCR analysis. Total RNA was extracted using 
RNeasy Mini Kit (Qiagen, UK) (liver and placenta samples) or RNeasy Lipid Tissue Mini Kit (Qiagen, 
Manchester, UK) (adipose tissue) and then reverse transcribed into cDNA with random hexamers using 
SuperScript II Reverse Transcriptase (Thermo Fisher Scientific, UK) in accordance with the 
manufacturers’ protocols. Real-time quantitative PCR reaction were performed on Viia7 system (Thermo 
Fisher Scientific, UK), in a 384-well assay format using SYBR Green Mastermix (Sigma-Aldrich, UK). 
Relative mRNA levels were calculated using the comparative Ct method normalized to cyclophilin. 
Primer sequences are available upon request.. 
 
Western blotting. Total cell lysates were prepared using RIPA buffer (Sigma-Aldrich, UK) supplemented 
with a Protease Inhibitor Cocktail (Sigma-Aldrich, UK) as well as Phosphatase Inhibitor Cocktails 2 and 
3 (Sigma-Aldrich, UK). Samples were separated on a 12% SDS-polyacrylamide gel and transferred to a 
nitrocellulose membrane. Membranes were hybridized with rabbit anti-ATGL (2138, 1:1000, Cell 
Signalling Technology, UK), rabbit anti-Phospho-HSL (Ser563) (4139, 1:1000, Cell Signalling 
Technology),  rabbit anti-HSL (4107, 1:1000, Cell Signalling Technology, UK),mouse anti-LXRα 
(ab41902, 1:1000 dilution;  Abcam, UK), rabbit anti-LXRβ (ab28479, 1:500; Abcam, UK) and mouse 
anti-GAPDH (MAB374, 1:80000; Millipore, UK) antibodies at 4o C overnight to detect expression, 
followed by 1 hour incubation at room temperature with goat anti-mouse (sc-2005, 1:4000; Santa Cruz 
Biotechnology, UK) and goat anti-rabbit (P0448, 1:2000, DAKO, UK) peroxidase-conjugated antibodies. 
Proteins were detected by chemiluminescence (Millipore, UK).   
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Statistical analysis. All values were expressed as mean +/- SEM for biological replicates. Unpaired two-
tailed t-test was used for single comparisons while multiple comparisons were analyzed using multiple 
measures of ANOVA with Newman-Keuls post-hoc testing. 
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Results 
Alterations in serum and hepatic lipids during mouse pregnancy. To examine the impact of pregnancy on 
murine lipid metabolism, serum lipids were profiled in mice at different stages of pregnancy:  day 7 post-
coitum, corresponding to early pregnancy (EP) and days 10, 14 and 18 post-coitum taken to represent 
advanced pregnancy (AP). Virgin female mice were used as non-pregnant controls. During pregnancy, 
serum triglyceride concentrations were unchanged in early pregnancy and then gradually increased 
starting from day 10 of mouse pregnancy onwards (Table 1). In contrast, total cholesterol levels decreased 
in early pregnancy (at day 7), and were further reduced in advanced gestation. The same pattern was 
observed in the abundance of cholesterol in HDL. Serum levels of free fatty acids were not significantly 
altered during pregnancy. Since the liver functions as a metabolic hub which regulates all domains of 
lipid homeostasis (2, 34), the temporal changes in hepatic lipid profiles in pregnant mice were examined. 
In early pregnancy, hepatic triglyceride and cholesterol content was significantly increased whereas the 
levels of free fatty acids remained unchanged (Table 1).  During advanced pregnancy, concentrations of 
hepatic triglyceride and cholesterol returned to pre-conception levels.  
 
Alterations in the hepatic LXR transcriptome during pregnancy. Throughout pregnancy the expression of 
LXR target genes involved in hepatic lipogenesis follow a distinct biphasic pattern. In early pregnancy, 
consistent with the early-gestational increase in hepatic triglycerides, the transcript levels of the lipogenic 
targets Fas and Scd1 were substantially raised (Figure 1A). In contrast, during advanced pregnancy the 
mRNA abundance of Srebp1c, Fas and Scd1 was markedly diminished.  
 
LXR controls hepatic cholesterol homeostasis by regulating the scavenger receptor B1 (SRB1), a 
membrane-bound glycoprotein which mediates the selective and efficient uptake of cholesteryl esters 
specifically from HDL, as well as the ATP-binding cassette G5 and G8 (ABCG5 and ABCG8) canalicular 
half-transporters, which form an obligate functional heterodimer that mediates the efflux of hepatic free 
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cholesterol into bile (3, 21). Similar to the lipogenic genes, the cholesterol efflux genes Abcg5, Abcg8 and 
Srb1 were also significantly downregulated during advanced pregnancy in mouse livers when compared 
to non-pregnant controls (Figure 1B). In contrast, the mRNA expression of the ATP-binding cassette A1 
(Abca1; an LXR target gene encoding a transmembrane protein, which mediates the transfer of 
cholesterol and phospholipids to lipid-poor plasma carriers such as apolipoprotein A1 (4)) was 
significantly raised in early pregnancy and then returned to pre-conception levels during advanced 
gestation (data not shown). 
 
In the liver, LXRα is the dominant nuclear receptor isoform (1). Immunoblot analysis revealed that the 
dynamic alteration in the expression of bona fide targets in the liver during pregnancy were not 
accompanied by any changes in the protein levels of LXRα (data not shown). The protein abundance of 
LXRβ also remained unaltered thus excluding a potential compensatory role. 
 
Gene expression analysis revealed that pregnancy has no significant impact on the expression of either 
Lxr isoform or its targets in the duodenum (Abca1, Abcg5, Abcg8 and Niemann–pick c1 l1  (Npc1l1)) and 
primary blood monocytes (Abcg1, Srb1,  ADP-ribosylation factor like 7 (Arl7) and  LDL receptor 
(Ldlr))(data not shown) thereby suggesting that changes in LXR activity are unlikely to affect intestinal 
cholesterol absorption and the reverse transport of sterols from extrahepatic tissues during pregnancy. 
 
LXR remains transcriptionally active during pregnancy. After confirming that changes in the protein 
availability of LXR could not explain the diminished mRNA levels of hepatic LXR targets during 
advanced-to-late pregnancy, we tested whether the reduced transcription of these genes could result from 
loss of LXR function during pregnancy. In order to pharmacologically activate LXR during gestation, 
pregnant mice were fed standard chow diet or T0901317-supplemented diet for 7, 10, 14 and 18 days 
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following the identification of a copulatory plug. Non-pregnant female mice fed a T0901317 or chow diet 
for the same number of days were used as controls.  
 
Comparison of the pregnant T0901317-fed groups versus pregnancy-matched chow-fed groups revealed 
that the expression of LXR targets involved in lipogenesis (Srebp1c, Fas and Scd1) and cholesterol efflux 
(Abcg5 and Abcg8) was markedly increased. These data indicate that LXR is transcriptionally active 
during pregnancy and pharmacological activation of LXR is able to reverse the reduction in the mRNA 
levels of key metabolic genes in mouse liver in late pregnancy (Figure 2A and B). The gene expression 
changes were functionally confirmed by the significant increase in hepatic triglyceride levels and the 
reduction in hepatic cholesterol concentrations (Figure 2C). Serum lipid profiling revealed that treatment 
of pregnant mice with T0901317 raises the levels of circulating cholesterol without affecting the levels of 
circulating triglycerides; these observations are in agreement with previous reports detailing the effect of 
this synthetic LXR agonist on non-pregnant mice (2, 34). 
 
Activation of LXR contributes to early-pregnancy lipogenesis. To determine whether the adaptations in 
lipid metabolism observed during normal pregnancy are entirely LXR dependent and therefore 
completely reversed by the presence of T0901317, pregnant T0901317 mice were compared against non-
pregnant diet-matched controls.  
 
T0901317 mimics the gestational signal that promotes lipogenesis during early pregnancy.  Gene 
expression analysis showed that the mRNA levels of the lipogenic LXR targets Fas and Scd1 were not 
further upregulated in T0901317-fed mice in early pregnancy as compared to diet-matched non-pregnant 
controls (Figure 2A). Also, there were no differences in the hepatic triglyceride content of pregnant and 
non-pregnant mice challenged with the agonist-supplemented diet for 7 days (Figure 2C).  
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During advanced pregnancy, however, the T0901317 agonist was not able to reverse the gestational 
changes in triglyceride homeostatic pathways in the liver. Specifically, from day 10 onwards the 
expression of Srebp1c, Fas and Scd1 was significantly reduced in pregnant mice administered with 
T0901317 as compared to diet-matched non-pregnant controls (Figure 2A). Interestingly, serum lipid 
profiling revealed that the presence of T0901317 abrogated the gestational increase in circulating 
triglycerides during advanced pregnancy (Figure 2D). 
 
Pharmacological activation of LXR had a limited effect on the gestational adaptations in cholesterol 
metabolism.  Lipid profiling showed that the gestational increase in hepatic cholesterol levels on days 7 
and 10 of pregnancy were abrogated by the presence of T0901317. In contrast, this synthetic agonist was 
unable to reverse the gestational changes in the expression of cholesterol homeostatic genes in the liver as 
evidenced by the fact that the transcript abundance of the cholesterol transporters Abcg5, Abcg8 and Srb1 
was lower in pregnant T0901317-fed mice as compared to non-pregnant T0901317-fed controls during 
advanced pregnancy (Figure 2B). Administration of T0901317 to pregnant mice also did not interfere 
with the pregnancy-associated drop in serum cholesterol as evidenced by the fact that pregnant mice 
challenged with the agonist-supplemented diet had significantly lower circulating total cholesterol levels 
from day 10 onwards as compared to diet-matched non-pregnant controls (Figure 2D).  
 
Overall these results suggest that pharmacological activation of LXR mimics the early-pregnancy increase 
in lipogenesis. During advanced pregnancy, however, T0901317 appeared unable to compete with the 
gestational cues that signal the alterations in triglyceride and cholesterol metabolism and therefore the 
patterns of gestational adaptations in lipid homeostasis were preserved throughout this period.  
 
LXR is required for lipogenesis during pregnancy. To delineate the functional importance of LXR in the 
control of the gestational adaptations in fatty acid and cholesterol metabolism and also to investigate to 
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what extent the T0901317-induced effects during pregnancy were signaled directly via LXR, wild-type 
(WT) and Lxrα, β -/- (LXR DKO) were studied at different stages of pregnancy. All the mice in this study 
were maintained on a C57Bl/6 x Sv129 mixed background.  
 
In LXR DKO, the gestational adaptations in hepatic lipogenesis during both early and advanced gestation 
were lost as evidenced by the fact that no significant changes were detected in the expression of Srebp1c, 
Fas and Scd1 in the livers of pregnant mice as compared to non-pregnant controls (Figure 3A). Lipid 
quantification studies confirmed that in the absence of Lxrα, β all of the gestational changes in hepatic 
triglyceride levels were abolished (Figure 3C). Serum biochemical profiling also showed that the early-to-
mid-pregnancy (days 7 and 10) increase in serum triglyceride levels was lost in mice lacking Lxrα, β 
(Figure 3D).  
 
LXR is not required for the gestational adaptations in cholesterol metabolism. Study of WT and LXR 
DKO at different stages of pregnancy revealed that the absence of Lxrα, β had no impact on the 
gestational adaptations in cholesterol homeostasis. Both WT and LXR DKO mice showed significantly 
reduced expression of the cholesterol efflux transporters Abcg5, Abcg8 and Srb1 on days 14 and 18 of 
pregnancy (Figure 3B). Even though LXR DKO mice had increased levels of hepatic cholesterol, there 
were no significant pregnancy-induced changes in cholesterol abundance either in the wild-type mice or 
in the mutants (Figure 3C). Serum lipid profiling showed that in both WT and LXR DKO mice, the 
concentrations of total circulating cholesterol are significantly reduced during pregnancy from day 10 
onwards (Figure 3D). 
 
Absence of LXR in the mother causes fetoplacental dyslipidemia. It is recognized that exposure of fetuses 
to a dyslipidemic environment in utero causes enhanced fetal growth (19, 23, 39). Given that the absence 
of Lxrα, β interferes with maternal lipogenesis during pregnancy, we examined the effect of Lxrα, β 
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deficiency on physiology and metabolism of the fetoplacental unit on day 18 of gestation. Our results 
indicated that LXR DKO mice had increased placental weight accompanied with abnormal accumulation 
of triglycerides and free fatty acids in this organ (Figure 4A). The Lxrα, β heterozygous fetuses also had 
raised accumulation of cholesterol, triglycerides and free fatty acids in their livers (Figure 4B). 
Expression analysis revealed that fetuses heterozygous for Lxrα, β do not have significant changes in the 
mRNA levels of lipogenic genes (Srebp1c, Fas, Scd1, Acc1, diglyceride acyltransferase 1 and 2 (Dgat1 
and Dgat2) and cholesterol biosynthetic genes (sterol-regulatory element-binding protein 2 (Srebp2), 3-
hydroxy-3methylglutaryl coenzyme A reductase (Hmgcr) and lanosterol 14α-demethylase (Cyp51) in the 
liver (Figure 4C). Interestingly, there were no differences in the transcript abundance of Lxrα, the 
dominant isoform of LXR in the liver, in the heterozygous fetuses as compared to the wild-type controls; 
the expression of Lxrβ, however, was significantly downregulated.  
 
Having determined that the fetoplacental hyperlipidemia detected on day 18 of pregnancy in LXR DKO 
mice is unlikely to result from the augmented biosynthesis of lipids in the fetal liver, we tested whether 
this phenotype could arise from the deregulated lipid homeostasis in the mother.  Biochemical analysis of 
maternal serum showed that in LXR DKO mice there was marked increase in the levels of free fatty acids 
on day 18 of pregnancy (Figure 4D).  
 
Also, we examined whether the supraphysiological accumulation of free fatty acids in the serum of LXR 
DKO mice during advanced gestation could result from abnormalities in intestinal lipid absorption. 
mRNA quantification studies confirmed that Lxrα, β deficiency has no significant impact on the duodenal 
expression of key lipogenic targets (cluster of differentiation (Cd36), fatty acid transport protein (Fatp4), 
plasma membrane fatty acid binding protein (Fabp-pm), acetyl-CoA synthase 1 (Acs1), Dgat1 and Dgat2 
in mice on day 18 of pregnancy (data not shown). Similarly, there were no differences in the transcript 
abundance of genes involved in intestinal cholesterol absorption (Abcg5, Abcg8 and Srb1) between 
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mutant mice and controls during advanced gestation; the expression of Niemann–pick c1 l1 (Npc1l1) was 
significantly downregulated in the duodena of LXR DKO mice. 
 
LXR plays a key role in the regulation white adipose tissue metabolism (6), therefore we investigated 
whether the supraphysiological accumulation of fatty acids in the serum later in pregnancy could result 
from the deregulated lipolysis in the white adipose tissue of the mutant mice. Our results confirmed that 
expression of the intracellular lipases monoglycerol lipase (Mgl), adipose triglyceride lipase (Atgl) and 
hormone sensitive lipase (Hsl) was considerably increased in the maternal white fat depots of LXR DKO 
mice (Figure 4E). Protein quantification studies confirmed that the levels of ATGL in the adipose tissue 
of mice deficient in Lxrα, β were significantly increased (Figure 4F); no changes in HSL phosphorylation 
were detected (data not shown). 
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Discussion 
In the present study, we have identified that changes in LXR signaling influence early-pregnancy 
lipogenesis in mice. We have shown that pharmacological activation of LXR disrupts lipid biosynthetic 
pathways in the liver and prevents early-pregnancy hypertriglyceridemia. We have also demonstrated that 
absence of LXR deregulates maternal lipid homeostasis and enhances white adipose tissue lipolysis which 
results in the increased accumulation of lipids in the fetal liver.  
 
In this report we demonstrate that LXR targets contribute to early pregnancy lipogenesis as evidenced by 
increased hepatic expression of Fas and Scd1, key enzymes involved in fatty acid biosynthesis, on day 7 
of mouse gestation and concurrent early-pregnancy accrual of hepatic triglycerides. Previous studies have 
demonstrated that SCD1 is the rate-limiting enzyme in the biosynthesis of monounsaturated fatty acids 
which are major components of complex lipids such as diglycerides, triglycerides and cholesteryl esters 
(22). Also, there is increased mRNA expression of Scd1 in the fatty livers of mice with genetically-
induced obesity (11). Similarly, FAS catalyzes the biosynthesis of saturated fatty acids from simple 
precursors and as such has been categorized as the “gatekeeper” of de novo lipogenesis. Studies in rodents 
have demonstrated that FAS contributes to the storage of hepatic triglycerides and approximately 11% of 
the total triglyceride content in the liver is derived from de novo lipogenesis (12). FAS has an even more 
pronounced role in lipogenesis in the context of fatty livers as evidenced by the fact that ob/ob mice have 
enhanced Fas transcript abundance (17). Based on the presence of a molecular environment established as 
conducive to hepatic lipogenesis and also the direct quantification of the increment of lipogenic products 
(hepatic triglycerides) we have concluded that there is increased fatty acid biosynthesis in the livers of 
early-pregnant mice. Moreover, the absence of raised free fatty acid and triglyceride concentrations in the 
serum of pregnant mice suggests that the hepatic lipids are unlikely to result from dietary lipids and 
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peripheral fats stored in adipose tissue that flow to the liver by way of the plasma free fatty acid pool or 
from intestinally derived chylomicron remnants. 
As pregnancy progressed, the transcript abundance of the tested lipogenic LXR targets was substantially 
reduced and this change was reflected by the decrease in hepatic triglyceride concentrations. During 
advanced pregnancy, the levels of serum triglycerides increase significantly and this change is not 
mirrored by an increase in the hepatic triglyceride content. Similarly, the molecular environment of the 
liver (i.e. the mRNA levels of Srebp1c, Fas and Scd1) suggest reduced hepatic de novo lipogenesis in 
advanced murine pregnancy.  These data are in agreement with previous studies (15). Moreover, it has 
been demonstrated that mice consume progressively greater amounts of food as gestation advances (20), 
and therefore it is likely that the elevated concentrations of circulating triglycerides result from the 
increased transfer of intestinally derived dietary lipids. These gestational adaptations occurred while the 
protein availability of both LXRα and LXRβ remained constant.  
Having identified Srebp1c, Fas and Scd1 as factors involved in the dynamic regulation of triglyceride 
homeostasis during mouse pregnancy, we aimed to determine whether LXR is involved in control of these 
adaptations. Administration of the synthetic LXR agonist T0901317 confirmed that LXR is indeed 
transcriptionally active throughout gestation and therefore it could play a role in the gestational alterations 
in murine lipid homeostasis. Our data showed that the presence of T0901317 interfered with the early-
pregnancy increase in Fas and Scd1 transcription and subsequent triglyceride accumulation.  
Our results indicate that the pregnancy signals which downregulate the expression of hepatic lipogenic 
factors during advanced pregnancy are potent enough to compete with T0901317-mediated activation of 
LXR . At present, there is limited understanding of how different maternal and placental hormones 
influence metabolic adaptations in the mother. Since the reduction in the expression of hepatic LXR 
targets parallels the completion of placenta formation it is likely that factors of placental origin signal 
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these adaptations directly, by binding to the LXR receptor itself, or indirectly, by initiating downstream 
signaling cascades which alter the phosphorylation state of LXR and thereby affect its activity.  
Deletion of Lxrα, β abrogates all the changes in hepatic triglyceride homeostasis during murine 
pregnancy. This result indicates that during pregnancy LXR is a key factor which relays the signals of 
reproductive hormones to the lipid metabolic network of the liver. Serum lipid profiling also 
demonstrated that mice lacking LXR have deregulated lipogenesis early in pregnancy, as evidenced by 
the fact that the increase in circulating triglycerides observed in wild-type mice on gestational days 7 and 
10 was lost in the global mutants. Gene expression analysis confirmed that in the absence of LXR, the 
transcript abundance of lipogenic genes in the liver do not exhibit any significant fluctuation in 
pregnancy. The results from our study could not exclude the possibility that gestational signals could the 
expression of lipogenic targets independent of LXR in late pregnancy, as evidenced by the trends for 
diminished transcript abundance of Srebp1c, Fas and Scd1 in LXR DKO mice on gestational days 14 and 
18. 
LXR is a master regulator not only of fatty acid and triglyceride metabolism, but also of cholesterol 
homeostasis (27, 30, 32, 40). Our data demonstrate that gestational adaptations in cholesterol metabolism 
are independent of LXR. Expression of the cholesterol efflux transporters Abcg5, Abcg8 and Srb1 was 
downregulated during pregnancy independent of T0901317 challenge or Lxrα, β deletion. Furthermore 
circulating total cholesterol concentrations were reduced during advanced pregnancy in all of our 
experimental models. Moreover, our data suggest that gestational changes in the expression of hepatic 
Abca1 are unlikely to contribute to the pregnancy adaptations in cholesterol homeostasis. Also, the 
expression of this transporter in the duodenum remains unchanged throughout pregnancy (data not 
shown). These results are important as although the liver is the major source of plasma HDL, intestinal 
enterocytes also play a role in the biogenesis of this lipoprotein and 30% of the circulating HDL is 
derived from the intestine in an ABCA1- dependent manner (5).  Thus, we have concluded that changes 
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in LXR signalling do not play a role in the gestational adaptations in cholesterol homeostasis. Further 
studies are necessary to elucidate the molecular mechanisms that influence cholesterol homeostasis during 
pregnancy. 
 
Our data also revealed that defects in maternal lipid metabolism as a consequence of Lxrα, β deletion 
cause fetoplacental dyslipidemia in mice. Previous studies have demonstrated that LXR is expressed in 
white adipose tissue where it is involved in the regulation of cholesterol, free fatty acid and glucose 
metabolism (6). In vivo studies have reported that pharmacological activation of LXR increases adipose 
tissue lipolysis and fatty acid β-oxidation (37). We show that mice lacking both LXR isoforms have 
increased white adipose tissue lipolysis later in pregnancy, as evidenced by the raised maternal serum 
fatty acid levels and the upregulated expression of intracellular lipases in the white fat of these mice.  
Moreover, we demonstrated that Lxrα, β deficiency increases the protein levels of ATGL (a key lipolytic 
enzyme which controls energy homeostasis by catalyzing the rate-limiting step in triglyceride catabolism 
(14)) in the adipose tissue of pregnant mice.  Our data suggest that changes in HSL phosphorylation are 
unlikely to contribute to the enhanced lipolytic response in adipose tissue of the Lxrα, β mutant miceOur 
conclusion that Lxrα, β deficiency promotes white fat lipolysis during advanced gestation is consistent 
with the observed in vivo phenotype (i.e increased serum free fatty acid concentrations and reduced 
adipose tissue mass) as wells as the obtained gene and protein expression data. Furthermore, the precise 
regulation of whole-body lipid homeostasis depends on the continuous crosstalk between liver and 
adipose tissue. Therefore, we could speculate that the increase in white fat lipolysis in the pregnant LXR 
DKO mice could occur as a mechanism to compensate for the defects in hepatic lipogenesis in the mother 
and protect the fetus from any deficiencies in nutrient supply. 
 
A key result from this study was that LXR DKO mice have increased placental weight and enhanced fatty 
acid and triglyceride accumulation in the placenta later in pregnancy. We also showed that fetuses from 
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LXR DKO mice have increased free fatty acids, triglycerides and cholesterol in the liver. Given that there 
was no induction of lipid biosynthetic pathways in the livers of the Lxrα, β heterozygous fetuses, it is 
likely that the fetal hepatic hyperlipidemia is a result of the deregulated maternal lipid homeostasis and 
impaired placental function. Consistent with this, a recent study has linked maternal hyperlipidemia with 
placental abnormalities and adverse fetal outcomes in cases of gestational diabetes mellitus (GDM) 
(35).Moreover, previous studies suggest that maternal adipose tissue lipolytic products are predominantly 
utilized as ketogenic substrates and the resulting ketone bodies get rapidly transferred to the fetal 
circulation where they act as lipogenic precursors and energy fuels (15). Maternally-derived free fatty 
acids are also able to cross the placenta and accumulate in the fetoplacental compartment (16).  Our 
results excluded the possibility that the genetic background of the heterozygous fetuses could contribute 
to their hyperlipidemic phenotype since the mRNA expression of all fatty acid and cholesterol 
biosynthetic genes, as well as Lxrα, was the same as in the wild-type controls. Previous studies have 
shown that gestational pathologies such as GDM and obesity, where maternal plasma levels of circulating 
lipids are supraphysiologically raised, are associated with fetal overgrowth (large-for-gestational age 
infants) (13, 28, 33, 36). Specifically, obese pregnant women typically have significantly increased levels 
of circulating triglycerides in combination with reduced HDL-cholesterol levels and hyperglycemia as a 
consequence of exacerbated peripheral insulin resistance in the third trimester of gestation (29). The 
transplacental delivery of nutrients is quantitatively and qualitatively altered as a result of the increased 
total lipid content and the accumulation of macrophages and proinflammatory mediators in the placentas 
of obese women leading to the birth of infants increased neonatal fa t mass and body fat percentage) (8, 
24). Moreover, offspring of women with obesity and/or GDM are not only prone to adverse side effects at 
birth such as preterm delivery (10) and stillbirth (2)  but also have a high risk of developing obesity, 
impaired glucose tolerance, and type 2 diabetes later in life (4, 7). All of these reports underscore the 
importance of thoroughly understanding the molecular determinants of alterations in maternal and fetal 
lipid metabolism during pregnancy in order to prevent immediate and long-term metabolic diseases. Our 
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study identifies LXR as an attractive candidate which can be targeted with therapeutic interventions in 
order to reverse maternal and fetal dyslipidemia. 
 
In conclusion, we present for the first time evidence that LXR is a factor essential for early-pregnancy 
lipogenesis in mice. We demonstrate that deletion of LXR not only interferes with the pregnancy 
adaptations in triglyceride metabolism in the liver but also causes fetoplacental dyslipidemia as a 
consequence of the raised maternal white fat lipolysis.   
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Table 1: Adaptations in serum and hepatic lipid profiles during mouse pregnancy. Total 
triglycerides, free fatty acids, cholesterol and HDL-cholesterol measured in mouse serum and hepatic 
lipid extracts.  
 
Figure 1: Increased expression of lipogenic LXR targets in mouse liver during early pregnancy. A. 
Lipogenic genes.  B. Cholesterol homeostatic genes. Results are represented as mean ± SEM (n=6-8) *p< 
0.05, **p < 0.01, ***p < 0.001, comparison of pregnant groups (day (D) 7-18) versus non-pregnant group 
(D0). P value determined by one-way ANOVA with Newman-Keuls post-hoc testing. 
 
Figure 2: Pharmacological activation of LXR mimics early-pregnancy lipogenesis in mice. A. 
Expression of lipogenic genes. B. Expression of cholesterol homeostatic genes. C. Total cholesterol and 
triglyceridespregnant T0901317-fed group. Results are represented as mean ± SEM (n=6-8); a p<0.05 
comparison of non-pregnant T0901317-fed groups (day (D) 7-18) versus non-pregnant group D0; b 
p<0.05 comparison of pregnant T0901317-fed groups (D7-18) versus pregnant group D0; c p<0.05 
comparison pregnant T0901317-fed group vs corresponding non-pregnant T0901317-fed group. P value 
determined by one-way ANOVA with Newman-Keuls post-hoc testing. 
 
Figure 3: LXR is required for lipogenesis during early mouse pregnancy. A. Expression of lipogenic 
genes. B. Expression of cholesterol homeostatic genes. C. Total cholesterol and triglycerides measured in 
hepatic lipid extracts. D. Total triglycerides and cholesterol measured in mouse serum. a p< 0.05 
comparison of pregnant wild-type (WT) groups (day (D) 7-18) vs non-pregnant WT controls (D0); b  p< 
0.05 comparison of pregnant LXR DKO groups (D7-18) vs non-pregnant LXR DKO controls (D0); c  p< 
0.05 comparison LXR DKO group vs corresponding WT group. P value determined by one-way ANOVA 
with Newman-Keuls post-hoc testing. 
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Figure 4: Gestational adaptations in LXR signaling protect against abnormalities in fetoplacental 
lipid metabolism in mice. A. Placenta weight and total cholesterol, triglycerides and free fatty acids 
measured in mouse placenta. B. Total cholesterol, triglycerides and free fatty acids measured in fetal 
hepatic extracts. C. mRNA expression of genes involved in de novo lipogenesis and cholesterol synthesis 
in fetal liver. D. Levels of free fatty acid in maternal serum. E. Expression of intracellular lipases in white 
adipose tissue. F. Protein levels of ATGL in white adipose tissue. Results are represented as mean ± SEM 
(n=4-8). *p< 0.05, **p < 0.01, ***p < 0.001, comparison of wild-type (WT) vs LXR DKO group. P value 
determined by unpaired t-test. 
Table 1: Adaptations in serum and hepatic lipid profiles during mouse pregnancy
Non-pregnant Early Pregnancy Advanced Pregnancy
D0 D7 D10 D14 D18
Serum
Triglycerides (mmol/ L) 0.80 ± 0.04 0.76 ± 0.11 1.16 ± 0.06 * 1.34 ± 0.16 ** 1.46 ± 0.13 ***
Free fatty acids (mmol/L) 0.81 ± 0.06 0.94 ± 0.09 1.07 ± 0.08 0.82 ± 0.09 0.93 ± 0.03
Total cholesterol (mmol/L) 2.13 ± 0.12 1.80 ± 0.06 *** 0.71 ± 0.05 *** 1.33 ± 0.04 *** 0.97 ± 0.04 ***
HDL-cholesterol (mmol/L) 2.13 ± 0.06 1.70 ± 0.07 *** 0.57 ± 0.05*** 1.32 ± 0.04 *** 1.05 ± 0.04 ***
Liver
Triglycerides (µmol/g) 990.11 ± 37.73 1324.50 ± 119.98 * 1280.56 ± 89.90 1058.96 ± 73.03 994.93 ± 143.46
Free fatty acids (µmol/g) 222.63 ± 39.49 202.18 ± 26.80 286.68 ± 29.12 318.29 ± 31.14 203.59 ± 31.52
Cholesterol (µmol/g) 54.93 ± 2.65 109.58 ± 14.45 ** 103.03 ± 13.24 ** 77.74 ± 5.20 83.31 ± 10.22
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Figure 3: LXR is required for lipogenesis during early mouse pregnancy
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Figure 4: Gestational adaptations in LXR signalling protect against abnormalities in
fetoplacental lipid metabolism in mice
